X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
FE-203799 (apraglutide) is a once-weekly , a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog. It is being evaluated for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease.
Lead Product(s): Apraglutide
Therapeutic Area: Immunology Product Name: FE-203799
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
FE-203799 (apraglutide) is an investigational, next-generation, long-acting synthetic GLP-2 analog. It is being evaluated for the treatment of short bowel syndrome with intestinal failure.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE-203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Ironwood Pharmaceuticals
Deal Size: $1,000.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition December 12, 2023
Details:
Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Ironwood Pharmaceuticals
Deal Size: $1,000.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition May 22, 2023
Details:
Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.
Lead Product(s): Apraglutide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Asahi Kasei Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
FE203799 (apraglutide) is an investigational new drug that is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and working capital.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 18, 2022
Details:
VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and working capital.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 13, 2022
Details:
Apraglutide is investigational new drug that is next-generation, long-acting synthetic GLP-2 analog being developed for range of rare gastrointestinal diseases.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
VectivBio intends to use the net proceeds, together with its existing cash and cash equivalents, available for sale and short-term deposits: to fund clinical development and pre-commercialization activities for its lead product candidate FE203799 (Apraglutide).
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 15, 2022
Details:
FE203799 (apraglutide) is a next-generation, synthetic GLP-2 analog rationally designed with the potential to offer an improved safety and efficacy profile relative to other agents in its class and less frequent dosing.
Lead Product(s): Apraglutide
Therapeutic Area: Immunology Product Name: FE203799
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
The company entered into agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure, steroid-refractory acute graft-versus-host disease in Japan.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Asahi Kasei Pharma
Deal Size: $200.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement March 30, 2022
Details:
Apraglutide, long-acting GLP-2 analog, is well-tolerated and does not require dose-adjustment in patients with renal disease, also demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available therapies.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
Data support regenerative, non-immunosuppressive hypothesis for clinical evaluation; launched Phase 2 STARGAZE clinical study of apraglutide in steroid-refractory GI aGVHD following FDA clearance of the company’s Investigational New Drug (IND) application.
Lead Product(s): Apraglutide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
VectivBio plans to initiate a Phase 2 trial evaluating apraglutide for the treatment of aGVHD in the first quarter of 2022.
Lead Product(s): Apraglutide
Therapeutic Area: Immunology Product Name: FE203799
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Details:
Proceeds will fund the Phase III program of apraglutide, a potential best-in-class GLP-2 analog, as well as global commercialization and business development activities.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Surveyor Capital
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
